CompletedPhase 4

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Cameroon41 participantsStarted 2021-07-30

Plain-language summary

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Loa loa blood microfilariae of between 5,000 - 18,000 per mL Exclusion Criteria: * known allergy to ivermectin; severe comorbidities

What they're measuring

Cross-reactive Antigenemia

Timeframe: 7 days

Trial details

NCT IDNCT05085665

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-31

Results submitted2022-08-30

View on ClinicalTrials.gov More Loiasis trials